Apollomics

APLM · NASDAQ

$22.05−$0.3881 (−1.73%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $22.44

APLM analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Nov 7, 2024

Bull case

Apollomics Inc., a clinical-stage biopharmaceutical company, showcases promising advancements in oncology therapies, particularly with vebreltinib (APL-101) and uproleselan (APL-106). Vebreltinib has demonstrated an impressive 66.7% objective response rate (ORR) in its Phase 1/2 trials, outperforming comparable MET inhibitors, which have shown ORRs of 40-55%, thereby indicating its potential to address significant unmet medical needs in MET-amplified cancers. Furthermore, uproleselan's ability to enhance chemotherapy efficacy in acute myeloid leukemia through the blockade of E-selectin presents additional avenues for successful treatment options, contributing positively to Apollomics's overall growth prospects.

Bear case

Apollomics Inc. is projected to experience significant net losses, with expectations of $2.11 per share for 2023 and $0.66 per share for 2024, raising concerns regarding its financial health. The company faces numerous risks, including potential negative clinical data, slower development timelines, setbacks in clinical studies, and the possibility of regulatory approval failures, which could hinder its growth and profitability. Additionally, the company's reliance on equity financing and the risk of dilution, coupled with a complex corporate structure, contribute to a challenging outlook for investors.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.